Dr. Love is board certified in Pediatric Cardiology by the American Board of Pediatrics.
Areas of Expertise
Pediatric Interventional Catheterization, Electrophysiology and Arrhythmia, Syncope, and Adult Congenital Heart Disease
In the News
Dr. Love discusses pediatric heart problems in The Daily News feature The Daily Check Up.
View the PDF.
American Board of Pediatrics
MD, University of Western Ontario
Children's Hospital of Montreal
Fellowship, Pediatric Cardiology
Children's Hospital Boston
Chinese (Other), English, French, Hebrew, Indian (Hindi), Korean, Spanish
GORE Septal Occluder Clinical Study: A Study to evaluate safety and efficacy in treatment of transcatheter closure of ostium secundum atrial septal defects (ASDs)
The purpose of this study is to determine the safety and effectiveness of the GORE Septal Occluder when used to close atrial septal defects. This study device is being evaluated to see if it will close ASDs without surgery. Researchers will look to see if the study de...
AMPLATZER Duct Occluder II in patients with a patent ductus arteriosus clinical study (ADO II Clinical Study)
The purpose of this study is to implant an experimental device called the AMPLATZER Duct Occluder II into a study participant's body to try to close their PDA. An experimental device is one that has not been approved by the U.S. Food and Drug Administration (FDA) for general use ...
Triedman JK, Alexander ME, Love BA, Collins KK, Berul CI, Bevilacqua LM, Walsh EP. Influence of patient factors and ablative technologies on outcomes of radiofrequency ablation of intra-atrial reentrant tachycardia in patients with congenital heart disease. Journal of the American College of Cardiology 2002 June 5; 39(11): 1827-1835.
Gillis AM, Phillipon F, Cassidy MR, Singh N, Dorion P, Love BA, Kerr CR. Canadian Working Group on Cardiac Pacing. Guidelines for Implantable cardioverter defibrillator follow-up in Canada: a consensus. Statement of the Canadian Working Group on Cardiac Pacing. Canadian Journal of Cardiology 2003; 19(1): 21-37.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Love during 2015 and/or 2016. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.